Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding AG    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
10/11/2019 10/14/2019 10/15/2019 10/16/2019 10/17/2019 Date
289.3(c) 288.2(c) 290.25(c) 285.7(c) 288.4 Last
1 586 783 2 094 277 1 528 064 3 202 479 2 188 452 Volume
+0.71% -0.38% +0.71% -1.57% +0.95% Change
More quotes
Financials (CHF)
Sales 2019 61 328 M
EBIT 2019 22 030 M
Net income 2019 15 109 M
Debt 2019 2 697 M
Yield 2019 3,22%
Sales 2020 62 866 M
EBIT 2020 22 477 M
Net income 2020 15 213 M
Finance 2020 2 069 M
Yield 2020 3,35%
P/E ratio 2019 16,3x
P/E ratio 2020 16,6x
EV / Sales2019 4,03x
EV / Sales2020 3,85x
Capitalization 244 B
More Financials
Company
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists... 
Sector
Pharmaceuticals
Calendar
10/16 | 08:00amSales and Revenue Call
More about the company
Surperformance© ratings of Roche Holding AG
Trading Rating : Investor Rating :
More Ratings
Latest news on ROCHE HOLDING AG
11:36aGENENTECH : Announces FDA Approval of Xofluza (Baloxavir Marboxil) for People at..
BU
10:59aSHIONOGI : Filed for the Supplemental New Drug Application of XOFLUZA in Japan f..
AQ
10:59aROCHE : reports very strong sales growth in the first nine months of 2019 - outl..
AQ
10/16GLOBAL MARKETS LIVE : Roche, Bank of America, Alphabet, MGM…
10/16EUROPE MARKETS: European Stocks Slip On Pessimism Over Brexit Deal And U.S.-C..
DJ
10/16ROCHE : Says Outlook Is Improving as Revenue Grows
DJ
10/16Roche reports very strong sales growth in the first nine months of 2019 &ndas..
GL
10/15New Gilead Sciences CFO Expected to Pursue More Deals to Expand Portfolio
DJ
10/15ROCHE : Invitation to Roche's live audio webcast on Gazyva in lupus nephritis pr..
PU
10/14EUROPE : European stocks hit pause as trade doubts linger
RE
10/14GLOBAL MARKETS LIVE : Sophos, Mercedes, Facebook, Boeing…
10/14ROCHE : Phase III PEMPHIX Study Shows Genentech's Rituxan Superior to Mycophenol..
AQ
10/14ROCHE : Phase III PEMPHIX study shows Roche's MabThera/Rituxan (rituximab) super..
AQ
10/14ROCHE : Phase III PEMPHIX study shows Roche's MabThera/Rituxan (rituximab) super..
PU
10/09REMINDER : Invitation to Roche's 9 Months Sales 2019 Audio Webcast and Conferenc..
PU
More news
News in other languages on ROCHE HOLDING AG
10/16EN DIRECT DES MARCHES : Ipsen, Soitec, DBV Technologies, FDJ, Roche, Google, ..
10/16Gewinnmitnahmen belasten Roche-Aktien
10/16ROCHE : La valeur du jour en Europe ROCHE au plus haut grâce à une santé de fer
10/16Roche wächst dank neuer Mittel weiter stark - Ausblick abermals erhöht
10/16Le bon Roche recherché, après des résultats intermédiaires impressionnants
More news
Analyst Recommendations on ROCHE HOLDING AG
More recommendations
Sector news : Pharmaceuticals - NEC
11:34aJudge summons drug company CEOs to court to discuss opioid settlement
RE
10:51aTEVA PHARMACEUTICAL INDUSTRIES : UK arm recalls some batches of Ranitidine - Med..
RE
10:22aALLERGAN : Form 8.3 -
DJ
05:25aTeva to donate over $15 billion worth of drugs in opioid settlement - source
RE
02:49aJOHNSON & JOHNSON : J&J Seeks $4 Billion Opioid Settlement
DJ
More sector news : Pharmaceuticals - NEC
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 308,41  CHF
Last Close Price 285,70  CHF
Spread / Highest target 24,6%
Spread / Average Target 7,95%
Spread / Lowest Target -21,2%
EPS Revisions
Managers
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING AG19.25%245 163
JOHNSON & JOHNSON2.94%356 736
MERCK AND COMPANY10.52%216 224
PFIZER-16.75%200 998
NOVARTIS16.30%198 756
NOVO NORDISK AS18.97%122 115